Every Form 4 that Cryo-Cell International Inc. (CCEL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCEL filings page.
Cryo-Cell International Inc. Chairman and Co-CEO David Portnoy restructured his holdings on August 5, 2026 by transferring 600,191 common shares to the David Portnoy Irrevocable 2026 Trust Agreement. The trust borrowed $800,000.26, used to satisfy Portnoy’s indebtedness, and he personally guaranteed repayment. The reported $1.3329 per share value is simply the loan amount divided by the transferred shares and not their fair market value. Portnoy is not a beneficiary of the trust, cannot revoke it and, for Section 16 purposes, disclaims beneficial ownership of its shares except for any pecuniary interest. After the transfer he directly holds 247,438 shares, has several indirect positions, and retains stock options including 280,000 underlying shares at $12.27 and 150,000 underlying shares at $3.89 per share.
Cryo-Cell International VP Finance and CFO Jill M. Taymans exercised stock options to acquire 7,500 shares of Common Stock on May 28, 2026 at $3.10 per share. Following this exercise, she directly holds 52,896 Common Stock shares.
She also retains multiple outstanding stock option awards on Common Stock with exercise prices ranging from $3.54 to $8.00 per share and expiration dates between 2027 and 2031, covering several tranches of 7,000 to 20,000 underlying shares each, subject to stated vesting and performance conditions.
Cryo-Cell International Inc. director, Chairman and Co-CEO David Portnoy reported updated holdings and new equity awards. On January 7, 2026, he was granted two direct stock option awards: one for 50,000 shares and another for 150,000 shares of common stock, both with an exercise price of $3.89 per share and expirations in 2031.
The 50,000 options vest in three equal parts: upon grant, on January 7, 2027, and on January 7, 2028. The 150,000 options, granted under the Cryo-Cell 2022 Stock Incentive Plan, are split into three equal tranches that each require both time-based service and stock-price performance hurdles of $6, $8, and $10 per share, each measured over 20 consecutive trading days after the first, second, and third anniversaries of grant.
Cryo-Cell International's Chief Information Officer, Oleg Mikulinsky, reported new equity awards and existing holdings. On January 7, 2026, he received two grants of stock options on the company’s common stock at an exercise price of $3.54 per share, one for 10,000 options that vest in thirds on January 7, 2026, 2027 and 2028, and another for 20,000 options granted under the Cryo-Cell 2022 Stock Incentive Plan with three tranches tied to both time and stock-price performance hurdles at $6, $8, and $10 per share over specified 20-day periods. He also reports direct ownership of 104,349 common shares and several prior option awards with varying exercise prices and vesting schedules.
Cryo-Cell International Co-CEO Mark Portnoy reported new stock option grants and updated his holdings in company securities. On January 7, 2026, he was granted a stock option for 50,000 shares of common stock at an exercise price of $3.89 per share, expiring on January 7, 2031. This grant, made under the Cryo-Cell 2022 Stock Incentive Plan, is split into three equal tranches that each require both time-based vesting and stock price hurdles of $6, $8, and $10 per share over 20 consecutive trading days.
Portnoy also received a separate stock option for 25,000 shares at an exercise price of $3.89 per share, expiring January 7, 2031, which vests one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028. Following these grants, he reports 821,973 common shares held directly, 42,266 shares held indirectly via a 401(k), and 71,529 shares held indirectly by Capital Asset Fund #1 Limited Partnership, where he may be deemed a beneficial owner as general partner.
Cryo-Cell International disclosed new equity awards to its VP Finance and CFO, Jill M. Taymans. On January 7, 2026, she received two stock option grants at an exercise price of $3.54 per share. One grant covers 10,000 options that vest one-third on the grant date, one-third on January 7, 2027, and one-third on January 7, 2028. The second grant covers 20,000 options under the Cryo-Cell 2022 Stock Incentive Plan, split into three equal tranches that each require both time-based vesting and the stock reaching average closing prices of at least $6, $8, and $10 per share over 20 consecutive trading days, tied to the first, second, and third anniversaries of the grant. Taymans also reports 45,396 shares of common stock owned directly and multiple prior option awards with expirations ranging from 2026 to 2031.
Cryo-Cell International (CCEL) Chairman and Co-CEO David Portnoy filed a Form 4 reporting open-market purchases of common stock. On 11/20/2025, he acquired 289 shares at $4.00 per share, and on 11/21/2025 he acquired 800 shares at $4.04 and additional shares at $4.09 and $4.10, including purchases held as custodian for his son. Following these transactions, his directly held common stock increased to 847,629 shares, with additional indirect holdings through family accounts and various entities.
The filing also lists several stock option grants over prior years with exercise prices between $4.30 and $12.27, covering amounts such as 280,000 and 50,000 underlying shares, and expirations from 2027 to 2030. Some options vest over time on specified future dates, while one grant vests in full if the company’s share price reaches $25.00 during its seven-year term.
Cryo-Cell International (CCEL) director, 10% owner, and Chairman/Co-CEO David Portnoy reported open-market purchases of the company’s common stock. He bought 1,429 shares at $4.00 on 11/17/2025, 640 shares at $4.09 on 11/18/2025, and 1,921 shares at a weighted average price of $4.08 on 11/19/2025.
Following these transactions, he directly beneficially owns 846,540 common shares and also reports additional indirect holdings through various entities and family accounts. He further holds several stock option awards, including grants exercisable at prices ranging from $4.30 to $12.27 per share with expirations between 2027 and 2030 and vesting schedules tied to time and, in one case, the stock reaching $25.00 per share.
Cryo-Cell International (CCEL) insider David I. Portnoy (Director, 10% Owner, Chairman, Co-CEO) reported open-market purchases of common stock. He acquired 1,026 shares at $4.18 on 11/10/2025, 2,474 shares at a weighted average price of $4.13 on 11/11/2025, and 2,040 shares at a weighted average price of $4.12 on 11/12/2025. Following these trades, his direct beneficial ownership stands at 842,550 shares.
He also reports derivative holdings, including 280,000 stock options at $12.27 expiring 12/22/2028, which vest immediately if the stock reaches $25 during the seven-year term.
Cryo-Cell International (CCEL) reported insider purchases by Chairman and Co-CEO David I. Portnoy. He acquired 4,666 shares of common stock on 10/31/2025 at $4.45 and 5,000 shares on 11/04/2025 at a weighted average price of $4.40.
Following these transactions, Portnoy beneficially owned 837,010 shares directly. He also reports additional indirect holdings through entities and family accounts, as listed in the filing.
Cryo-Cell International (CCEL) filed a Form 4 reporting a director equity award. On 10/21/2025, director Daniel Mizrahi received a grant of stock options to purchase 5,300 shares at $4.35 per share, expiring on 10/21/2035. The options vest at a rate of 1/12 per month commencing on 10/21/2025.
Following the reported transactions, the reporting person directly beneficially owned 30,634 shares of common stock. The filing also lists prior option grants of 5,300 shares each dated 10/20/2021, 10/03/2022, 10/10/2023, and 10/29/2024 with exercise prices of $12.63, $6.50, $4.90, and $5.82, respectively.
Cryo-Cell International (CCEL) director reported a new stock option grant. On 10/21/2025, the director received options for 5,300 shares at an exercise price of $4.35, exercisable on 10/21/2025 and expiring on 10/21/2035. Following the reported transactions, the director directly beneficially owned 57,901 shares of common stock. The filing also lists multiple prior stock option awards with various exercise prices and maturities.